Epidemiological measures for assessing the dynamics of the SARS-CoV-2-outbreak: Simulation study about bias by incomplete case-detection.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
10
2021
accepted:
05
10
2022
entrez:
26
10
2022
pubmed:
27
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
During the SARS-CoV-2 outbreak, several epidemiological measures, such as cumulative case-counts (CCC), incidence rates, effective reproduction numbers (Reff) and doubling times, have been used to inform the general public and to justify interventions such as lockdown. It has been very likely that not all infectious people have been identified during the course of the epidemic, which lead to incomplete case-detection. We compare CCC, incidence rates, Reff and doubling times in the presence of incomplete case-detection. For this, an infection-age-structured SIR model is used to simulate a SARS-CoV-2 outbreak followed by a lockdown in a hypothetical population. Different scenarios about temporal variations in case-detection are applied to the four measures during outbreak and lockdown. The biases resulting from incomplete case-detection on the four measures are compared in terms of relative errors. CCC is most prone to bias by incomplete case-detection in all of our settings. Reff is the least biased measure. The possibly biased CCC may lead to erroneous conclusions in cross-country comparisons. With a view to future reporting about this or other epidemics, we recommend including and placing an emphasis on Reff in those epidemiological measures used for informing the general public and policy makers.
Identifiants
pubmed: 36288362
doi: 10.1371/journal.pone.0276311
pii: PONE-D-21-32057
pmc: PMC9604981
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0276311Déclaration de conflit d'intérêts
The authors have read the journal’s policy and have declared the following competing interests: TK received research grants from the Gemeinsamer Bundesausschuss (G-BA – Federal Joint Committee, Germany), the Bundesministerium für Gesundheit (BMG – Federal Ministry of Health, Germany) outside of the submitted work. He further has received personal compensation from Eli Lilly & Company, Teva Pharmaceuticals, Total Energies S.E., the BMJ, and Frontiers outside of the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Pulmonology. 2021 Mar-Apr;27(2):110-115
pubmed: 32540223
PLoS One. 2007 Aug 22;2(8):e758
pubmed: 17712406
BMJ. 2020 May 12;369:m1808
pubmed: 32398230
PLoS One. 2020 Sep 16;15(9):e0239026
pubmed: 32936811
Emerg Infect Dis. 2020 Aug;26(8):1912-1914
pubmed: 32330410
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437
Biom J. 2021 Mar;63(3):490-502
pubmed: 33258177
Emerg Infect Dis. 2004 Sep;10(9):1523-8
pubmed: 15498151